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Ji-Yu Li1†, Yu-Yang Li2†, Wei Jin3†, Qing Yang1, Zhi-Ming Shao3 and Xing-Song Tian1*Abstract
Background: Acquired radioresistance of cancer cells remains a fundamental barrier to attaining the maximal
efficacy of radiotherapy for the treatment of breast cancer. Anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, play an
important role in the radioresistance of cancer cells. In the present study, we aimed to determine if ABT-737, a
BH3-only mimic, could reverse the acquired radioresistance of the breast cancer cell line MDA-MB-231R by
targeting Bcl-2 and Bcl-xL.
Methods: The radiosensitivity of MDA-MB-231 and MDA-MB-231R cells was compared using colony formation
assays. Reverse-transcription PCR and western blot were performed to detect the expression of Bcl-2 and Bcl-xL in
the cancer cell lines. Annexin V flow cytometric analysis and caspase-3 colorimetric assay were used to evaluate
apoptosis of the cancer cells. Cell viability was measured using the Cell Counting Kit-8. The animals used in this
study were 4 to 6-week-old athymic female BALB/c nu/nu mice.
Results: The MDA-MB-231R cells were more radioresistant than the MDA-MB-231 cells, and Bcl-2 and Bcl-xL were
overexpressed in the MDA-MB-231R cells. While ABT-737 was able to restore the radiosensitivity of the
MDA-MB-231R cells in vitro and in vivo experiment, it was not able to enhance the radiosensitivity of the
MDA-MB-231 cells. In addition, ABT-737 increased radiation-induced apoptosis in the MDA-MB-231R cells. Bcl-2 and
Bcl-xL were down regulated in the MDA-MB-231R cells following treatment with ABT-737.
Conclusions: Targeting of the anti-apoptotic proteins Bcl-2 and Bcl-xL with ABT-737 may reverse the acquired
radioresistance of MDA-MB-231R cells in vitro and in vivo. These findings suggest an attractive strategy for
overcoming the acquired radioresistance of breast cancer cells.
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Breast cancer is one of the most common malignant can-
cers among women worldwide. In 2012, an estimated
220,000 individuals were diagnosed with breast cancer
and the mortality associated with breast cancer is nearly
40,000 in the United States [1]. Radiotherapy plays an
important role in the treatment of breast cancer. Several
randomized clinical trials have shown that improved
disease-free and overall survival rates were improved by
the addition of radiotherapy in the treatment of women
with breast cancer [2-5]. However, tumor radioresistance* Correspondence: txs0509@163.com
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reproduction in any medium, provided the orremains a fundamental barrier to attaining maximal effi-
cacy with radiotherapy for the treatment of breast cancer.
Radioresistance may be present at the beginning of ther-
apy, causing the patients to fail to respond to treatment
(intrinsic radioresistance), or it may emerge over time dur-
ing radiotherapy treatment (acquired radioresistance).
Fractionated radiation (FR) is often used in radiotherapy
to facilitate the recovery of normal tissues. Cancer cells
may acquire radioresistance during fractionated radiother-
apy, which results in treatment failure. Overcoming the
acquired radioresistance of breast cancer could improve
the outcome of breast cancer patients who receive
radiotherapy.
Apoptosis, or programmed cell death, is the mechanism
of radiation-induced cancer cell death [6,7]. It is regulated
by complex interactions between anti-apoptotic proteinshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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teins including Bax, Bak, Bad and Bim [8,9]. Down regula-
tion of anti-apoptotic proteins can promote apoptosis and
enhance the radiosensitivity of cancer cells [10-13]. The
disruption of anti-apoptotic pathways is a novel target for
overcoming radioresistance in breast cancer.
ABT-737 is a rationally designed small molecule that
binds with high affinity to Bcl-2 and Bcl-xL and antago-
nizes their anti-apoptotic function, thereby inducing
apoptosis in many cancer cell types [14,15]. Recently, an
increasing number of studies have focused on the role of
ABT-737 in cancer therapy.ABT-737 have been shown
to reverse acquired paclitaxel resistance in breast cancer
cell lines [16]. Combined with rapamycin, ABT-737 has
been shown to enhance the radiosensitivity of non-small
cell lung tumors by inducing apoptosis [16,17].
To our knowledge, there have been no prior studies
investigating the effect of ABT-737 in combination with
radiotherapy for the treatment of breast cancer. In the
present study, we addressed whether ABT-737 could re-
verse the acquired radioresistance in breast cancer cells
with the aim of develop a new strategy to address the
serious clinical problem of acquired radioresistance in
breast cancer.Methods
Cell culture, materials and reagents
The human breast cancer cell line MDA-MB-231 was
purchased from the American Type Culture Collection.
The cells were grown in Leibovitz’s L-15 medium
(11415–064, GIBCO) supplemented with 10% fetal bo-
vine serum (FBS) (10099–158, GIBCO) and maintained
in a humidified 5% CO2 atmosphere at 37°C. ABT-737
was purchased from Santa Cruz Biotechnology, Inc (SC-
207242).Generation of radioresistant cells
MDA-MB-231 cells (1 × 106) were plated in 75 cm2 cul-
ture flasks and irradiated with 4Gy of γ-rays using a
Theratron Cobalt-60 treatment unit at a dose rate of
1 Gy per minute when the cells were at approximately
60% confluence in the culture flask. Immediately follow-
ing irradiation, the culture medium was renewed, and
the cells were returned to the incubator. When the
MDA-MB-231 cells reached approximately 90% conflu-
ence, they were trypsinized, counted and passaged into
new culture flasks. Again, the cells were treated with 4
Gy γ-rays when they reached approximately 60% conflu-
ence. The irradiation was performed 13 times for a total
dose of 50 Gy (irradiated with 2 Gy of γ-rays at the final
irradiation) over 5 months. The parental cells were tryp-
sinized, counted and passaged under the same condi-
tions without irradiation.Clonogenic assay for radiosensitivity
The cells were seeded in 6-well cell culture plates and
incubated for 2 weeks at 37°C after the receiving various
doses of irradiation. The colonies were fixed with pure
ethanol and stained with 1% crystal violet, washed and
air-dried. Colonies consisting of 50 or more cells were
counted as clonogenic survivors. The surviving fraction
(SF) was calculated by dividing the number of colonies
by the number of cells seeded and then multiplying by
the plating efficiency. Triplicate experiments were per-
formed independently.
Western blottings
Western blottings using rabbit anti-human Bcl-2 antibody
(#2876, Cell Signalling Technology) and rabbit anti-human
Bcl-xL antibody (556361, BD Biosciences) were performed
according to standard protocols. Chemiluminescent detec-
tion was performed and images were captured by the FUJI-
FILM LAS-3000 system (Fujifilm, Tokyo, Japan).
Extraction of RNA and RT –PCR
Total RNA was extracted using TRIzol reagent (Invitrogen)
according to the manufacturers’ recommendations. RT-
PCR(Reverse-Transcription PCR) was used to compare
the relative mRNA expression of Bcl-2 and Bcl-xL in
breast cancer cell lines. The primer sequences used were:
Bcl-2, sense, 50- GTGAACTGGGGGAGGATTGT-30 and
antisense, 50- GGAGAAATCAAACAGAGGCC-30 and
Bcl-xL, sense, 5
0-CCCAGAAAGGATACAGCTGG-30 and
antisense, 50- GCGATCCGACTCACCAATAC-30. Thirty-
two cycles of PCR were performed using the program of
30 s at 94°C, 30 s at 56°C and 1min at 72°C. The PCR
products were electrophoresed on 2% agarose gel and
imaged using a ChemiImag 5500 Imaging System (Alpha
Innotech, San Leandro, CA, USA).
Apoptosis assay
MDA-MB-231 and MDA-MB-231R cells (1 × 106) were
plated in 10 mm dishes for each data point. Following
incubation overnight at 37°C, the cells were treated with
ABT-737 (1 μM, 24 hours) and irradiated with 4 or 12 Gy.
After 24 h, apoptotic analyses were performed by flow
cytometry, as described previously [18], using a FACS
Calibur system (Becton Dickinson Biosciences, San Diego,
CA) with ModFit LT™ software (Verity Software House,
Inc., Topsham, ME). The apoptotic cells were analyzed by
using quadrant statistics on the propidium iodide-negative
and Annexin V-positive cells.
Caspase-3 colorimetric assay
The cells were collected and washed with phosphate-
buffer saline (PBS, pH 7.2). After centrifugation, the
caspase 3 colorimetric assays were performed according
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using a Sunrise Microplate Reader(Tecan US, Inc.,
Charlotte, NC).
Cell viability
Cell viability was evaluated using Cell Counting
Kit-8 (CCK-8; Dojindo Molecular Technologies Inc.,
Gaithersburg, MD) assay. The cells were plated in 96-
well plates at 1 × 104 cells/well with media only,
media with ABT-737 (1 μM) or DMSO, which were
changed with media 24 hours later. To evaluate cell
viability, 10 μl of CCK-8 was added per well, and the
cells were incubated for an additional 4 hours, Fol-
lowing the incubation, the absorbance at 450 nm was
recorded using a 96-well plate reader (Sunrise Micro-
plate Reader, Tecan US, Inc.,Charlotte, NC).
Animal experiments
The animals used in this study were 4 to 6-week-old
athymic female BALB/c nu/nu mice which were pro-
vided by the Shanghai Institute of Materia Medica,
Chinese Academy of Science. MDA-MB-231R cells (106)
were implanted into the mammary fat pad. Twenty-four
nude mice were divided into 4 groups for this study,
with each group having 6 mice. The four groups were
the ABT-737 group, the ABT-737 plus radiation group,
the DMSO plus radiation, and the DMSO group. Fourteen
days following tumor inoculation, DMSO and ABT-737
were administered intraperitoneally at doses of 20 mg/kg
for 7 consecutive days. The mice receiving radiation were
irradiated 1 hour after ABT-737 or DMSO treatment with
2 Gy daily over 5 consecutive days. The tumors on the
mice were irradiated using γ-rays (Theratron 1000E
Cobalt-60 treatment unit, Canada). The non-tumor parts
of the mice were shielded with lead blocks. The rate of
tumor growth was determined by plotting the means of
two orthogonal diameters of the tumors, which were mea-
sured at 7-day intervals. The animals were monitored for
tumor growth and general health every 2 days for up to 6
weeks. The tumor volumes were calculated using the fol-
lowing formula: volume = 0.52 × width2 × length. The ani-
mals were sacrificed and autopsied 6 weeks after
tumor inoculation. All studies on mice were conducted
in accordance with the National Institutes of Health
‘Guide for the Care and Use of Laboratory Animals’.
The study protocol was approved by Shanghai Medical
Experimental Animal Care Committee.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS) software Version
11.5 for Windows (SPSS Inc., Chicago, IL). ANOVA
and Student’s t-tests were conducted to determine the
statistical significance of the differences between theexperimental groups. A value of p < 0.05 was considered
statistically significant. The graphs were created using
GraphPad Prism 5.
Results
Morphology and radiosensitivity of MDA-MB-231R cells
The radioresistant cells, designated MDA-MB-231R,
were obtained by subjecting MDA-MB-231 cells to 5
months of fractioned irradiation with a total dose of
50 Gy and 10 additional passages without irradiation.
No obvious change in the cell morphology was observed
following irradiation (Figure 1A). The radiosensitivity of
MDA-MB-231 and MDA-MB-231R cells were compared
using a colony formation assay (Figure 1B). Each point
on the survival curve represents the mean surviving
fraction from triplicate experiments. As expected, the
MDA-MB-231R cells had a higher survival rate than
MDA-MB-231 cells, indicating that the MDA-MB-231R
cells were more radioresistant than the MDA-MB-231
cells.
Bcl-2 and Bcl-xL are overexpressed in MDA-MB-231R cells
Because anti-apoptotic proteins could enable the radio
resistance of the cancer cells, we investigated whether the
expression of Bcl-2 and Bcl-xL, important proteins
involved in apoptosis, were altered in the MDA-MB-231R
cells. Western blotting showed a significant increase in
Bcl-2 and Bcl-xL expression in the MDA-MB-231R cells
compared to MDA-MB-231 cells (Figure 2A). These
results were further verified by RT-PCR (Figure 2B). These
findings suggest that the overexpression of anti-apoptotic
proteins, including Bcl-2 and Bcl-xL, is important for the
acquisition of radioresistance by cancer cells.
ABT-737 restores the radiosensitivity of MDA-MB-231R cells
Colony formation assays were used to determine if
ABT-737 could restore the radiosensitivity of the MDA-
MB-231R cells. As shown in Figure 3A, the colony-
forming ability of the MDA-MB-231R cells greatly
decreased following treatment with 1 μM of ABT-737 for
24 hours. This result indicated that the radiosensitivity of
the MDA-MB-231R cells was significantly increased fol-
lowing treatment with ABT-737. The cell viability assays
demonstrated that ABT-737 was able to reverse the
acquired radioresistance of the MDA-MB-231R cells.
The radiation-induced decrease in cell viability was
enhanced by a 24 hour pre-treatment with 1 μM ABT-
737 (Figure 3B).
ABT-737 does not enhance the radiosensitivity of MDA-
MB-231 cells
We further investigated whether ABT-737 could enhance
the radiosensitivity of MDA-MB-231 cells. The colony for-
mation assays revealed that the radiosensitivity of the
Figure 1 Morphology and radiosensitivity of MDA-MB-231R cells. (A) No obvious change in the cell morphology was observed following
radiation. (B) The radioresistant MDA-MB-231R cells had a higher survival rate than the non-radioresistant MDA-MB-231 cells.
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treatment with ABT-737 (Figure 4A). The cell viability
assays further demonstrated that ABT-737 did not en-
hance the radiosensitivity of MDA-MB-231 cells
(Figure 4B).Figure 2 Bcl-2 and Bcl-xL are overexpressed in MDA-MB-231R
cells. (A) Western blot analysis showed that the anti-apoptotic
proteins Bcl-2 and Bcl-xL are overexpressed in the MDA-MB-231R
cells compared with MDA-MB-231 cells. Lane 1, MDA-MB-231 cells;
lane 2, MDA-MB-231R cells. (B) RT-PCR analysis further confirmed an
overexpression of Bcl-2 and Bcl-xL in the MDA-MB-231R cells. Lane 1,
marker; lane 2, MDA-MB-231cells; lane 3, MDA-MB-231R cells.ABT-737 increases the radiation-induced apoptosis of
MDA-MB-231R cells
Annexin V flow cytometric analysis was used to determine
if ABT-737 could enhance the radiation-induced apoptosis
of MDA-MB-231R cells. The MDA-MB-231R cells were
treated with DMSO or 1 μM ABT-737 for 24 hours prior
to radiation (0, 4, or 12 Gy). As shown in Figure 5A, the
proportion of Annexin V-positive and propidium iodide-
negative cells (apoptotic cells) was significantly higher in
the ABT-737-treated group than in the untreated and
DMSO control groups. A caspase-3 colorimetric assay was
performed to confirm our findings. The activity of caspase
3 was significantly upregulated after treatment with ABT-
737.These data suggest that ABT-737 increased the
radiation-induced apoptosis of the MDA-MB-231R cells.
Bcl-2 and Bcl-xL are down-regulated in MDA-MB-
231R cells and are unchanged in MDA-MB-231 cells fol-
lowing ABT-737 treatment.
To evaluate the effect of ABT-737 on the apoptotic path-
way, we examined the expression of Bcl-2 and Bcl-xL in
MDA-MB-231R and MDA-MB-231 cells following treat-
ment with ABT-737. We found that ABT-737 directly
downregulated Bcl-2 and Bcl-xL expression in the MDA-
MB-231R cells in a time-dependent manner. The expression
of Bcl-2 and Bcl-xL in the MDA-MB-231R cells gradually
decreased over 24 hours of treatment with 1 μM ABT-737
(Figure 6A). In contrast, the expression of Bcl-2 and Bcl-xL
in the MDA-MB-231 cells did not change after ABT-737
treatment (Figure 6B). These results indicate that ABT-737
reversed the acquired radioresistance of the MDA-MB-231R
cells by downregulating the expression of Bcl-2 and Bcl-xL.ABT-737 can reverse the acquired radioresistance of
breast cancer cells in vivo
To investigate whether ABT-737 could reverse acquired
radioresistance of breast cancer cells in vivo, we used an
Figure 3 ABT-737 restores the radiosensitivity of MDA-MB-231R cells. (A) The colony forming ability of the MDA-MB-231R cells was
significantly decreased following 1 μM ABT-737 for 24 hours. (B) Cell viability assays demonstrated that pre-treatment with ABT-737 increases
radiation-induced cell death in the MDA-MB-231R cells. *P < 0.05. Columns, mean of three independent experiments; bars, SD.
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shown in Figure 7, the MDA-MB-231R tumors in the
DMSO group of mice were similar to the tumors in the
DMSO plus radiation group. This indicated that the
MDA-MB-231R tumors were radioresistant. The tumors
in the ABT-737 group were not significantly different
from those in the DMSO group. The tumors in the
ABT-737 plus radiation group grew at a slower rate than
the tumors in the DMSO plus radiation group. Taken to-
gether, these results suggested that ABT-737 could re-
verse the radioresistance of MDA-MB-231R tumors.
Discussion
Fractionated radiation (FR) is used often in radiotherapy
treatment to facilitate the recovery of normal tissues,
while the repair of cancer cells is generally less efficient
between fractions. However, the acquired radioresistance
of cancer cells is thought to occur during the repopula-
tion of the tumor during the long-term FR [19]. The
proliferating cancer cells that repopulate the tumor may
be different subpopulation with a different genotype thatFigure 4 ABT-737 does not enhance the radiosensitivity of MDA-MB-2
ABT-737 treatment following radiation. (B) Cell viability assays demonstrate
cell death in the MDA-MB-231 cells. Columns, mean of three independentconfers radioresistance. Cancer cells with acquired
radioresistance many survive during radiotherapy and
lead to additional cancer recurrence after radiation ther-
apy, thus limiting the effectiveness of radiation therapy.
Therefore, to promote better outcomes for patients
undergoing radiotherapy, an effective strategy may be to
target the cells acquired radioresistance.
In the present study, the MDA-MB-231R cells were
obtained after fractionated radiation with total dose of
50 Gy and were cultured without radiation for the next
10 passages. The radioresistance of MDA-MB-231R cell
line was determined using a colony-forming assay. The
results of Western blot analysis showed that the anti-
apoptotic proteins Bcl-2 and Bcl-xL were overexpressed
in the MDA-MB-231R cells that had acquired radioresis-
tance. RT-PCR analysis confirmed that the expression of
the anti-apototic genes Bcl-2 and Bcl-xL were upregu-
lated in the radioresistant MDA-MB-231R cells and
overexpressed compared with their parental cell line.
The overexpression of anti-apoptotic proteins in the Bcl-
2 family is frequently observed in many different tumor31 cells. (A) Survival curves of the MDA-MB-231 cells with or without
d that pre-treatment with ABT-737 does not increase radiation-induced
experiments; bars, SD.
Figure 5 ABT-737 increases the radiation-induced apoptosis of MDA-MB-231R cells. (A) The proportion of Annexin V-positive and
propidium iodide-negative cells (apoptotic cells) was significantly higher in the ABT-737-treated group compared to the untreated and DMSO
control groups. (B) A caspase-3 colorimetric assay was performed to confirm our findings. The activity of caspase 3 was significantly upregulated
after treatment with ABT-737. Columns, mean of three independent experiments; bars, SD.
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therapy [20,21]. However, the molecular mechanism
underlying the acquired radioresistance of cancer cells
remains unclear. Several mechanisms are thought to
contribute to the acquired radioresistance, including
mutated p53 [22], amplification of DNA repair genes
[23], overexpression of the cell-cycle regulator protein,
cyclin D1 [19] and activation of pro-survival oncogenes
such as EGFR [24]. The overexpression of Bcl-2 and Bcl-
xL in the MDA-MB-231R cells indicated that these anti-
apoptotic proteins play an important role in the acquisi-
tion of radioresistance.
The expression of anti-apoptotic proteins is closely
related to the radiosensitivity of cancer cells, and target-
ing these proteins could be an effective method to
overcome radioresistance. An et al. overcame the radio-
resistance of prostate cancer cells by using HA14-1, aFigure 6 Bcl-2 and Bcl-xL are down-regulated in MDA-MB-231R cells
treatment. (A) The expression of Bcl-2 and Bcl-xL in MDA-MB-231R cells g
(B) In contrast, the expression of Bcl-2 and Bcl-xL in the MDA-MB-231 cellsnovel Bcl-2 inhibitor [10]. Anai et al. demonstrated that
down regulation of Bcl-2 could induce radiation sensitiv-
ity in prostate cancer cells [11]. The expression levels of
the anti-apoptotic proteins are also correlated with the
outcome of patients who received radiotherapy. Yang
et al. [25] reported that Bcl-2 expression is associated
with an increased risk of the local recurrence in patients
with early breast cancer that received breast conservative
surgery and radiotherapy. AT-101, a small molecule in-
hibitor of the Bcl-2 family members, enhanced the
radiation-induced apoptosis of human leukemia cells
[26]. We proposed that targeting the overexpression of
Bcl-2 and Bcl-xL may be an effective way to overcome
the acquired radioresistance of cancer cells. In this study,
it was observed that following treatment with 1 μM
ABT-737 for 24 hours, the colony formation ability
of MDA-MB-231R cells decreased greatly and theand are unchanged in MDA-MB-231 cells following ABT-737
radually decreased over 24 hours when treated with 1 μM of ABT-737.
did not change after ABT-737 treatment.
Figure 7 ABT-737 can reverse acquired radioresistance of breast cancer cells in vivo. The method of xenograft tumor volume
measurement, radiation and reagent administration are described in Methods section. The tumor volumes in the ABT-737 plus radiation group
were significant smaller than those in the DMSO plus radiation group (P < 0.01). However, the growth curves of the tumors in the DMSO group,
the DMSO plus radiation group and the ABT-737 group were very similar. In this study, six mice per group were used. Points, mean volumes;
bars, SD.
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gested that ABT-737 could reverse the acquired radiore-
sistance of MDA-MB-231R cells by increasing radiation-
induced apoptosis. In vivo, the growth tumors in the
ABT-737 plus radiation group were reduced compared
with the DMSO plus radiation group. However, in con-
trast to the results obtained with the MDA-MB-231R
cells, ABT-737 did not enhance the radiosensitivity of
the MDA-MB-231 cells. This could be attributed to the
down regulation of Bcl-2 and Bcl-xL expression
observed in MDA-MB-231R cells, but not in MDA-MB-
231 cells following ABT-737 treatment (Figure 6A and B).
The expression levels of Bcl-xL and Bcl-2 in the MDA-
MB-231 cells were very low, and treating them with ABT-
737 did not down regulate their expression. Although
treatment with ABT-737 did not enhance the radiosensi-
tivity of the MDA-MD-231 cells, it reversed the acquired
radioresistance of the MDA-MD-231R cells, making them
more likely to be killed by radiation treatment. Eliminating
these radioresistant cancer cells is perhaps the most effect-
ive method for decreasing the recurrence of cancer follow-
ing radiotherapy.
This is the first study to show that ABT-737 down
regulated the expression of Bcl-2 and Bcl-xL in cancer
cells in a time-dependent manner. ABT-737, a rationally
designed small molecule binds with high affinity to Bcl-2
and Bcl-xL, thereby antagonizing their anti-apoptotic
functions and inducing apoptosis in many types of can-
cer cell. ABT-737 binds to the multi-domain, anti-
apoptotic Bcl-2 family member proteins to prevent them
from sequestering the pro-apoptotic BH3-only proteins.
In the present study, we found that ABT-737 down
regulated the expression of Bcl-2 and Bcl-xL in MDA-
MB-231R cells in a time-dependent manner. Similar
results were obtained using SK-BR-3 and MCF-7 cells
(data not shown). The down regulation of those anti-apoptotic proteins by ABT-737 may at least partly explain
its ability to reverse the acquired radioresistance of the
MDA-MB-231R cells. Further studies are required to de-
termine the mechanisms underlying this phenomenon.
In summary, treatment with ABT-737 reversed the
acquired radioresistance of the MDA-MB-231R cells
both in vitro and in vivo. The data indicate the potential
benefit of ABT-737 treatment in conjunction with radio-
therapy for breast cancer treatment and suggest a new
strategy for improving the effectiveness of radiotherapy.
Conclusions
In summary, our results suggest that targeting the anti-
apoptotic proteins Bcl-2 and Bcl-xL with ABT-737 may
reverse the acquired radioresistance of MDA-MB-231R
cells in vitro and in vivo. These findings suggest an at-
tractive strategy for overcoming the acquired radioresis-
tance of breast cancer.
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